EUVIMEDEUVIMED entdecken
Open Access

Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor

Hongyu Li iD, Mayuree Rodrat iD, Majid K Al-Salmani iD, Diana-Florentina Veselu iD, Sangwoo T Han iD, Karen S Raraigh iD, Garry R Cutting iD, David N Sheppard iD

The Journal of Physiology · 2024

DOI: 10.1113/jp285727 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Physiology, 2024. Verfasst von Hongyu Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quinolones. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Cystic Fibrosis Foundation Therapeutics, Cystic Fibrosis Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Some residues in the cystic fibrosis transmembrane conductance regulator (CFTR) channel are the site of more than one CFTR variant that cause cystic fibrosis. Here, we investigated the function of S1159F and S1159P, two variants associated with different clinical phenotypes, which affect the same pore‐lining residue in transmembrane segment 12 that are both strongly potentiated by ivacaftor when expressed in CFBE41o − bronchial epithelial cells. To study the single‐channel behaviour of CFTR, we applied the patch‐clamp technique to Chinese hamster ovary cells heterologously expressing CFTR variants incubated at 27°C to enhance channel residence at the plasma membrane. S1159F‐ and S1159P‐CFTR formed Cl − channels activated by cAMP‐dependent phosphorylation and gated by ATP that exhibited thermostability at 37°C. Both variants modestly reduced the single‐channel conductance of CFTR. By severely attenuating channel gating, S1159F‐ and S1159P‐CFTR reduced the open probability ( P o ) of wild‐type CFTR by ≥75% at ATP (1 mM); S1159F‐CFTR caused the greater decrease in P o consistent with its more severe clinical phenotype. Ivacaftor (10–100 nM) doubled the P o of both CFTR variants without restoring P o values to wild‐type levels, but concomitantly, ivacaftor decreased current flow through open channels. For S1159F‐CFTR, the reduction of current flow was marked at high (supersaturated) ivacaftor concentrations (0.5–1 μM) and voltage‐independent, identifying an additional detrimental action of elevated ivacaftor concentrations. In conclusion, S1159F and S1159P are gating variants, which also affect CFTR processing and conduction, but not stability, necessitating the use of combinations of CFTR modulators to optimally restore their channel activity. image Key points Dysfunction of the ion channel cystic fibrosis transmembrane conductance regulator (CFTR) causes the genetic disease cystic fibrosis (CF). This study investigated two rare pathogenic CFTR variants, S1159F and S1159P, which affect the same amino acid in CFTR, to understand the molecular basis of disease and response to the CFTR‐targeted therapy ivacaftor. Both rare variants diminished CFTR function by modestly reducing current flow through the channel and severely inhibiting ATP‐dependent channel gating with S1159F exerting the stronger adverse effect, which correlates with its association with more severe disease. Ivacaftor potentiated channel gating by both rare variants without restoring their activity to wild‐type levels, but concurrently reduced current flow through open channels, particularly those of S1159F‐CFTR. Our data demonstrate that S1159F and S1159P cause CFTR dysfunction by multiple mechanisms that require combinations of CFTR‐targeted therapies to fully restore channel function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuinolonesCricetinaeAnimalsHumansCystic Fibrosis Transmembrane Conductance RegulatorCHO CellsCricetulusAmino AcidsIon Channel GatingAminophenolsAdenosine Triphosphate

Stichwörter der Autor:innen

CFTR chloride ion channelCFTR inhibitionCFTR potentiationcystic fibrosisivacaftor (VX-770)rare variant

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorivacaftorAmino AcidsAminophenolsAdenosine TriphosphateCFTR protein, humanQuinolones

Autor:innen und Institutionen

  • School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
  • Center of Research and Development for Biomedical Instrumentation, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
  • Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Al Khoudh, Muscat, Sultanate of Oman.
  • School of Biochemistry, University of Bristol, Bristol, UK.
  • Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Hongyu Li, Mayuree Rodrat, Majid K Al-Salmani, Diana-Florentina Veselu, Sangwoo T Han, Karen S Raraigh, Garry R Cutting, David N Sheppard

Förderung

  • NIDDK NIH HHS
  • Cystic Fibrosis Foundation Therapeutics
  • Cystic Fibrosis Trust
  • Cystic Fibrosis Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Royal Golden Jubilee (RGJ) Ph.D. Programme
  • Ministry of Higher Education, Research and Innovation

Zitieren

APA

Li, H., Rodrat, M., Al-Salmani, M. K., Veselu, D. F., Han, S. T., Raraigh, K. S., Cutting, G. R., & Sheppard, D. N. (2024). Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor. The Journal of Physiology. https://doi.org/10.1113/jp285727

Vancouver

Li H, Rodrat M, Al-Salmani MK, Veselu DF, Han ST, Raraigh KS, et al. Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor. The Journal of Physiology. 2024. doi:10.1113/jp285727

BibTeX
@article{Li2024,
  author = {Li, Hongyu and Rodrat, Mayuree and Al-Salmani, Majid K and Veselu, Diana-Florentina and Han, Sangwoo T and Raraigh, Karen S and Cutting, Garry R and Sheppard, David N},
  title = {Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor},
  journal = {The Journal of Physiology},
  year = {2024},
  doi = {10.1113/jp285727}
}
Kostenlos starten →